Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease

MT Newswires Live02-02 17:34

Sanofi (SNY) said Monday venglustat met its primary goal in a phase 3 study involving adult and pediatric patients with neurological symptoms of type 3 Gaucher disease, but failed to meet the main goal in another study.

The company has been evaluating venglustat for type 3 Gaucher disease and Fabry disease, both rare inherited lysosomal storage diseases.

Sanofi said patients with type 3 Gaucher disease treated with venglustat showed statistically significant improvements in neurological function at 52 weeks, based on global assessment scores for ataxia and cognitive performance, compared with those receiving standard enzyme-replacement therapy.

The drug also performed as well as enzyme-replacement therapy on non-neurological outcomes, such as spleen and liver size and hemoglobin levels, meeting three of four key secondary endpoints, it added.

The drugmaker also said a phase 3 study of the drug in patients with Fabry disease showed reductions in neuropathic and abdominal pain, but the trial did not meet its primary endpoint.

The company said it plans to pursue global regulatory filings for venglustat in type 3 Gaucher disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608373852?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608373852","market":"sg","top_or_hot":-1,"title":"Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Monday venglustat met its primary goal in a phase 3 study involving adult and pediatric patients with neurological symptoms of type 3 Gaucher disease, but failed to meet the main goal in another study.</p><p>The company has been evaluating venglustat for type 3 Gaucher disease and Fabry disease, both rare inherited lysosomal storage diseases.</p><p><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said patients with type 3 Gaucher disease treated with venglustat showed statistically significant improvements in neurological function at 52 weeks, based on global assessment scores for ataxia and cognitive performance, compared with those receiving standard enzyme-replacement therapy.</p><p>The drug also performed as well as enzyme-replacement therapy on non-neurological outcomes, such as spleen and liver size and hemoglobin levels, meeting three of four key secondary endpoints, it added.</p><p>The drugmaker also said a phase 3 study of the drug in patients with Fabry disease showed reductions in neuropathic and abdominal pain, but the trial did not meet its primary endpoint.</p><p>The company said it plans to pursue global regulatory filings for venglustat in type 3 Gaucher disease.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-02 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Monday venglustat met its primary goal in a phase 3 study involving adult and pediatric patients with neurological symptoms of type 3 Gaucher disease, but failed to meet the main goal in another study.</p><p>The company has been evaluating venglustat for type 3 Gaucher disease and Fabry disease, both rare inherited lysosomal storage diseases.</p><p><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said patients with type 3 Gaucher disease treated with venglustat showed statistically significant improvements in neurological function at 52 weeks, based on global assessment scores for ataxia and cognitive performance, compared with those receiving standard enzyme-replacement therapy.</p><p>The drug also performed as well as enzyme-replacement therapy on non-neurological outcomes, such as spleen and liver size and hemoglobin levels, meeting three of four key secondary endpoints, it added.</p><p>The drugmaker also said a phase 3 study of the drug in patients with Fabry disease showed reductions in neuropathic and abdominal pain, but the trial did not meet its primary endpoint.</p><p>The company said it plans to pursue global regulatory filings for venglustat in type 3 Gaucher disease.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608373852","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608373852","pubTimestamp":1770024862,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  said Monday venglustat met its primary goal in a phase 3 study involving adult and pediatric patients with neurological symptoms of type 3 Gaucher disease, but failed to meet the main goal in another study.The company has been evaluating venglustat for type 3 Gaucher disease and Fabry disease, both rare inherited lysosomal storage diseases.Sanofi said patients with type 3 Gaucher disease treated with venglustat showed statistically significant improvements in neurological function at 52 weeks, based on global assessment scores for ataxia and cognitive performance, compared with those receiving standard enzyme-replacement therapy.The drug also performed as well as enzyme-replacement therapy on non-neurological outcomes, such as spleen and liver size and hemoglobin levels, meeting three of four key secondary endpoints, it added.The drugmaker also said a phase 3 study of the drug in patients with Fabry disease showed reductions in neuropathic and abdominal pain, but the trial did ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4588":"碎股","SNY":"赛诺菲安万特","BK4585":"ETF&股票定投概念"},"translate_title":"赛诺菲表示Venglustat达到了3型戈谢病3期研究的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"SNYNF":1.5},"content_text":"Sanofi (SNY) said Monday venglustat met its primary goal in a phase 3 study involving adult and pediatric patients with neurological symptoms of type 3 Gaucher disease, but failed to meet the main goal in another study.The company has been evaluating venglustat for type 3 Gaucher disease and Fabry disease, both rare inherited lysosomal storage diseases.Sanofi said patients with type 3 Gaucher disease treated with venglustat showed statistically significant improvements in neurological function at 52 weeks, based on global assessment scores for ataxia and cognitive performance, compared with those receiving standard enzyme-replacement therapy.The drug also performed as well as enzyme-replacement therapy on non-neurological outcomes, such as spleen and liver size and hemoglobin levels, meeting three of four key secondary endpoints, it added.The drugmaker also said a phase 3 study of the drug in patients with Fabry disease showed reductions in neuropathic and abdominal pain, but the trial did not meet its primary endpoint.The company said it plans to pursue global regulatory filings for venglustat in type 3 Gaucher disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608373852","isCrawlerRequest":true}